KRTL Biotech Highlights ELIXIR as Flagship Hydration Product in Bolivia

Rhea-AI Summary

KRTL Biotech (OTC: KRTL) has announced its flagship hydration product ELIXIR as a major success in the Bolivian market. The GMP-compliant hydration beverage is currently available in over 7,000 retail locations throughout Bolivia, offering a scientifically formulated blend of electrolytes including glucose, sodium, potassium, calcium, magnesium, and citric acid.

ELIXIR comes in multiple flavors and formats, from sachets to 625ml bottles, and has positioned itself as both a hangover recovery solution and cocktail mixer. The company is now preparing for international expansion, particularly targeting the U.S. market, and is working on regulatory compliance with FDA requirements for packaging, ingredient disclosures, and health claims.

Positive

• None.

Negative

• Currently limited to Bolivian market only
• Pending FDA regulatory approvals needed for U.S. market entry
• Will face significant competition in the saturated U.S. beverage market

Lakewood, CO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- KRTL Holding Group Inc. (OTC: KRTL) ("KRTL Holding" or the "Company") today announced that its subsidiary, KRTL Biotech, Inc., is spotlighting ELIXIR, a high-performance electrolyte hydration beverage, as one of its most commercially successful and strategically positioned consumer health products in the Bolivian Market

Produced under GMP-compliant conditions at KRTL Biotech’s Bolivian facility, ELIXIR is a non-alcoholic, hypertonic hydration beverage designed to rapidly restore essential electrolytes and combat dehydration caused by intense physical activity, heat exposure, or alcohol consumption. With a proprietary formula containing glucose, sodium, potassium, calcium, magnesium, and citric acid, ELIXIR is scientifically formulated to hydrate cells more efficiently than traditional sports drinks.

Currently available in more than 7,000 retail drugstores, major supermarkets, and club stores throughout Bolivia, ELIXIR has earned a reputation as both a hangover recovery essential and a popular mixer in cocktails. Its vibrant branding and broad consumer appeal have made it a mainstay in nightclubs, gyms, and family households alike.

"ELIXIR represents the intersection of scientific hydration and lifestyle relevance," said Cesar Herrera, CEO of KRTL Holding Group Inc. "It’s not only a formulation rooted in health science but also a brand with a strong cultural footprint in Bolivia and a compelling case for expansion."

The ELIXIR lineup includes flavors such as Berry, Arándano, Citrus Punch, Tropical Flavor, Mango Zero (no sugar), and Electro Mandarina in sachet format. The variety of packaging—from single-serve sachets to sleek 625ml bottles—makes ELIXIR suitable for retail shelves, on-the-go consumption, and hospitality applications.

KRTL Biotech is preparing to initiate structured pathways for international market introduction, including regulatory entry into the United States. The U.S. market for hydration solutions, functional wellness beverages, and alcohol recovery aids continues to expand, offering strong demand signals for ELIXIR's unique formulation and branding. As part of this strategy, KRTL Biotech is assessing packaging compliance, ingredient disclosures, and permissible health claims to align with FDA labeling requirements. In parallel, the Company is also developing an import framework and market positioning strategy to support commercial rollout once regulatory alignment is complete.

"As a company rooted in both science and innovation, we’re proud to see ELIXIR emerge as a household name in Bolivia," said Patricia Wilstermann, CEO of SIGMA. "Its evolution from a pharmaceutical concept to a cultural staple represents exactly the kind of product innovation we aim to scale globally."

"We see ELIXIR as more than a product—it’s a proven platform for wellness and recovery," said Daniel Bishop, CEO of KRTL Biotech. "With real-world adoption and scalable production already in place, it offers us a clear path to enter functional beverage markets globally."

For more on ELIXIR, visit the brand's Instagram at @elixir.bo or follow them on Facebook at facebook.com/elixir.

About KRTL Holding Group, Inc.

KRTL Holding Group, Inc. (OTC: KRTL) operates through its subsidiaries KRTL Biotech, Inc. and KRTL International Corp. The Company leverages strategic synergies across biotech, technology, and emerging markets to drive growth and deliver shareholder value.

About KRTL Biotech, Inc.

KRTL Biotech, Inc. focuses on building scalable life-science operations that prioritize quality, compliance, and innovation. The company aims to expand its international footprint while maintaining rigorous U.S. reporting and regulatory standards.

About Industria Químico Farmacéutica SIGMA Corp SRL

SIGMA is a Bolivian pharmaceutical manufacturer with more than five decades of experience in formulation, quality manufacturing, and commercialization of essential and complementary health products, including pharmaceuticals and nutraceuticals.

For more information:

www.krtlholding.com | www.krtl-icc.com | www.krtlbiotech.com | www.sigmacorp.com.bo/en/about

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to differ materially from any future results, performance, or achievements expressed or implied by these forward-looking statements. Words such as “anticipates,” “will,” “believes,” “plans,” “expects,” “intends,” “projects,” “estimates,” “future,” and “opportunity” and similar expressions are used to identify these forward-looking statements. Forward-looking statements are not guarantees of future performance. These risks and uncertainties include, but are not limited to, changes in regulatory requirements, market conditions, and other factors described in the Company’s filings. Additional information concerning risks and uncertainties that could materially affect KRTL’s business and financial results is included in the Company’s filings with the OTC Markets and, where applicable, the SEC. You should not place undue reliance on forward-looking statements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

www.krtlholding.com
info@krtlholding.com

www.krtlbiotech.com
info@krtlbiotech.com

www.krtl-icc.com
info@krtl-icc.com

FAQ

What is KRTL's ELIXIR product and what makes it unique?

ELIXIR is a hypertonic hydration beverage containing a proprietary blend of glucose, sodium, potassium, calcium, magnesium, and citric acid, designed for rapid electrolyte restoration. It's produced under GMP-compliant conditions in Bolivia.

How many retail locations carry KRTL's ELIXIR in Bolivia?

ELIXIR is available in over 7,000 retail locations across Bolivia, including drugstores, major supermarkets, and club stores.

What flavors of ELIXIR does KRTL currently offer?

ELIXIR comes in several flavors including Berry, Arándano, Citrus Punch, Tropical Flavor, Mango Zero (sugar-free), and Electro Mandarina in various packaging formats.

What are KRTL's plans for ELIXIR's international expansion?

KRTL is preparing for international expansion, primarily focusing on entering the U.S. market. The company is working on FDA compliance, packaging requirements, and developing an import framework.

Where is ELIXIR manufactured?

ELIXIR is manufactured at KRTL Biotech's GMP-compliant facility in Bolivia through their partnership with SIGMA, a Bolivian pharmaceutical manufacturer.